cerrar
Tagged with GE

New Billion Dollar Pharma Action Fund to Counter ‘Slow…
June 9th 2020 saw the launch of a new action fund on antimicrobial resistance (AMR), with 23 leading biopharmaceutical companies committing to almost…

Jeong-Sun Seo – Chairman, Macrogen & President, KoreaBIO
Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO), explains the basis for Korea’s…

Sangrae Cho – CEO, Gencurix
Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae Cho, discusses the importance of…

Merck KGaA: Big-Ticket Investments in Manufacturing Scale &…
Merck KGaA has moved to continuously expand its manufacturing capacity and capability in recent years with a number of headline-grabbing investments…

Yeul-Hong Kim – Director, K-MASTER, South Korea
Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data for Korean oncology professionals.…

Exploring New & Repurposed Tools in the Fight Against…
Dr Sophia Ononye-Onyia explains why a combination of both repurposed drugs and emerging technologies like 3D bioprinting and artificial intelligence…

US Generics: Company Culture Key to Attracting Talent
Two leading executives in the US generics market outline why robust company culture is key to attracting top talent that might otherwise gravitate…

Top 5 RNA-Based Biopharma Companies
Below we present a list of the top 5 public biopharma companies that focus on developing RNA-based therapies. RNA interference (RNAi) is a natural…

SCM Lifescience: A Global Approach to Korean Regenerative…
Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in several global M&A deals in…

Jisoo Pae – CEO, Genome & Company
Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr Jisoo Pae, its co-founder and CEO,…

Top Italian Pharma Companies
Italy's pharma industry consistently ranks among the top 10 globally, with domestic companies making up a significant share. These, largely private…

Korean Corestem Targets US Market for Ground-Breaking ALS…
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here